SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Bull-like who wrote (8225)10/8/1999 4:41:00 PM
From: Anthony Wong  Respond to of 9523
 
Not much, Bull. An earlier Reuters story said:

Doctors already prescribe Zoloft for post-traumatic stress,
experts said. Winning the new indication would give Pfizer more
freedom in marketing the drug but would spur only a tiny boost
from the current sales pace, analysts said.



To: Bull-like who wrote (8225)10/9/1999 10:57:00 AM
From: Brander  Read Replies (1) | Respond to of 9523
 
<I wonder how much ($ sense) this approval will expand Zoloft's market?>

Probably not as much as you might think. Physician's have been using Zoloft to treat PTSD for some time now.

The literature has supported its use for awhile, and I think it is used rather widely for this syndrome.

Perhaps some of the PCP's will use it more than some of the other SSRI's, now that it has an indication.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News